| Year |
Citation |
Score |
| 2021 |
Rago F, Rodrigues LU, Bonney M, Sprouffske K, Kurth E, Elliott G, Ambrose J, Aspesi P, Oborski J, Chen JT, McDonald ER, Mapa FA, Ruddy DA, Kauffmann A, Abrams T, ... Bhang HC, et al. Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia. Molecular Cancer Research : McR. PMID 34799403 DOI: 10.1158/1541-7786.MCR-21-0390 |
0.327 |
|
| 2020 |
Rago F, Elliott G, Li A, Sprouffske K, Kerr G, Desplat A, Abramowski D, Chen JT, Farsidjani A, Xiang KX, Bushold G, Feng Y, Shirley MD, Bric A, Vattay A, ... ... Bhang HC, et al. The discovery of SWI/SNF chromatin remodeling activity as a novel and targetable dependency in uveal melanoma. Molecular Cancer Therapeutics. PMID 32747420 DOI: 10.1158/1535-7163.Mct-19-1013 |
0.366 |
|
| 2019 |
Baltschukat S, Schacher Engstler B, Huang A, Hao HX, Tam A, Wang HQ, Liang J, DiMare MT, Bhang HC, Wang Y, Furet P, Sellers WR, Hofmann F, Schoepfer J, Tiedt R. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of Activation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30674502 DOI: 10.1158/1078-0432.Ccr-18-2814 |
0.325 |
|
| 2019 |
Rago F, DiMare MT, Elliott G, Ruddy DA, Sovath S, Kerr G, Bhang HC, Jagani Z. Degron mediated BRM/SMARCA2 depletion uncovers novel combination partners for treatment of BRG1/SMARCA4-mutant cancers. Biochemical and Biophysical Research Communications. 508: 109-116. PMID 30527810 DOI: 10.1016/J.Bbrc.2018.09.009 |
0.381 |
|
| 2019 |
Bhang HC, DiMare MT, Kodack DP, Tan L, Kerr G, Radhakrishna VK, Golji J, Ruddy DA, Yuan T, Niederst MJ, Korn JM, Porta DG, Hammerman PS, Engelman JA, Abrams T, et al. Abstract 394: In vivo shRNA screens under treatment pressure by BRAF and MEK inhibitors to identify novel combination treatment strategies for BRAF-mutant colorectal cancer Cancer Research. 79: 394-394. DOI: 10.1158/1538-7445.Sabcs18-394 |
0.339 |
|
| 2017 |
Kuiken HJ, Dhakal S, Selfors LM, Crowdis JP, Bhang HC, Stegmeier F, Mills GB, Brugge JS. Abstract 3957: Characterization of functional heterogeneity andin vivodynamics of clonal cell populations derived from the triple-negative breast cancer cell line MDA-MB-468 Cancer Research. 77: 3957-3957. DOI: 10.1158/1538-7445.Am2017-3957 |
0.301 |
|
| 2017 |
Rago F, Dimare MT, Bushold G, Kapoor A, Bhang HC, Jagani Z. Abstract 1025: Controlled and endogenous depletion of a synthetic lethal target in human cancer cell lines via SMASh degron engineering Cancer Research. 77: 1025-1025. DOI: 10.1158/1538-7445.Am2017-1025 |
0.324 |
|
| 2015 |
Caushi JX, Bhang HC, Li J, Kao I, Radhakrishna VK, Cooke VG, Korn JM, Ruddy DA, Kasibhatla S, Stegmeier F. Abstract 3240: Understanding clonal complexity of a tumor xenograft model via cellular barcoding technology Cancer Research. 75: 3240-3240. DOI: 10.1158/1538-7445.Am2015-3240 |
0.363 |
|
| 2015 |
Bhang HC, Ruddy DA, Radhakrishna VK, Zhao R, Kao I, Rakiec D, Shaw P, Balak M, Caushi JX, Ackley E, Keen N, Schlabach MR, Palmer M, Sellers WR, Michor F, et al. Abstract 2847: High complexity barcoding to study clonal dynamics in response to cancer therapy Cancer Research. 75: 2847-2847. DOI: 10.1158/1538-7445.Am2015-2847 |
0.354 |
|
| 2014 |
Chan HM, Jaffe JD, Wang Y, Zhang J, Huether R, Kryukov GV, Bhang HC, Taylor JE, Hu M, Englund NP, Yan F, Wang Z, McDonald ER, Wei L, Ma J, et al. Abstract 2930: Global chromatin profiling reveals NSD2 mutation in pediatric ALL Cancer Research. 74: 2930-2930. DOI: 10.1158/1538-7445.Am2014-2930 |
0.381 |
|
| 2011 |
Park J, Dvoracek C, Lee KH, Galloway JF, Bhang HC, Pomper MG, Searson PC. Imaging: CuInSe/ZnS Core/Shell NIR Quantum Dots for Biomedical Imaging (Small 22/2011) Small. 7: 3106-3106. DOI: 10.1002/Smll.201190087 |
0.318 |
|
| Show low-probability matches. |